Because of their embryological derivation from foregut the respiratory airways are regularly host to bacteria arriving in inspired air and aspirated from the naso-oropharynx. Should the first-line defence (mucociliary clearance) be less than perfect, such bacteria remain longer in the airway mucus and some are able to capitalize on this delay by compromising mucus transport further through the production of epithelium-damaging cilioinhibitory and ciliotoxic substances. Bacterial persistence in the airways elicits an inflammatory host response which causes further damage to the airway and results in a 'vicious circle' of progressive lung damage. Treatment hinges upon eliminating the bacteria in the mucus using antibiotics that penetrate mucus well (e.g. fluoroquinolones)-and considering adjunct therapy with antiinflammatory and mucokinetic agents.
Introduction
There is a co-evolutionary relationship between microbe and host in their mutual aim to survive. The microbe always has the evolutionary 'edge' by virtue of its ability to replicate rapidly and adapt. Man's respiratory defences are compromised by their derivation from those previously defending the foregut from which the respiratory tract is derived. The microorganism's best strategy for survival is quiet persistence rather than dramatic invasion, and it is from the states of chronic microbial colonization and infection that we can learn most about microbial tactics to achieve this state. Bronchiectasis, 1 irreversible dilation of a bronchus or bronchi, is an important cause of chronic bronchial infection, is a well-defined entity, and represents the ideal parasitic state for bacteria within the (normally sterile) bronchial tree. As such it provides an ideal model for examining man's interrelationships with microorganisms. 2 
Human and experimental models of bronchiectasis
Bronchiectasis is the final common pathway of inflammatory consequences of a number of known causes but in the UK over 60% of cases are idiopathic. Paradoxically, the vast majority of patients with bronchiectasis appear to be immunocompetent but to expectorate secretions containing microorganisms regarded as non-invasive. Such opportunistic bacteria are exemplified by non-typeable, unencapsulated Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis and mucoid Pseudomonas aeruginosa. Some of these are normal commensals in the oropharynx.
The answer to why such immunocompetent patients should be persistently colonized or infected with apparently non-invasive microorganisms may lie in the observation that the first-line sinobronchial defence mechanism of mucociliary clearance is severely impaired in patients with bronchiectasis. 3 A review of the known causes of bronchiectasis suggests that most could have their primary effect by reducing mucociliary clearance in the respiratory tract. So it is conceivable that such causes might result in a pathogenetic mechanism which is entirely independent of the presence of microorganisms in the normal sterile respiratory tract, the organisms being merely passengers as a result of compromised mucus clearance. However, an experimental model of bronchiectasis produced by partial ligation of the apical lobe of a rat clearly demonstrates that the evolution of bronchiectasis requires persistence of viable microorganisms. 4 Moreover, the microorganisms most readily achieving this disease in the model are those bacteria which are commonly isolated from the sputum of patients with bronchiectasis.
A hypothesis for the pathogenesis of bronchiectasis can be constructed from the observations in such models, based on initial reduction in mucociliary clearance by a variety of causal agents or underlying diseases.
'Vicious circle' hypothesis of the pathogenesis of bronchiectasis
A 'vicious circle' of events can explain the known facts about patients with bronchiectasis. 1, 2 An initial triggering insult with or without underlying genetic disease compromises the first-line bronchial defence mechanism, mucociliary clearance, allowing bacteria to remain for longer in the bronchial tree. This allows those microorganisms which are able to damage such clearance mechanisms directly to colonize the mucus, then stimulate the host to an inflammatory response. The inflammation becomes chronic because it fails to eliminate the colonists. It damages 'innocent bystander' lung and further impairs mucus clearance. Hence, microorganisms first use the tactic of direct damage to the host's respiratory tract and subsequently they subvert the host's normally protective inflammatory defence into one which damages the host's own respiratory tract-and so the bacteria achieve a parasitic state in the bronchial tree.
Direct microbial damage
A variety of mechanisms exist by which the non-invasive microorganisms commonly isolated from the sputum of patients with bronchiectasis are able to damage the respiratory mucosa directly by production of exotoxins-including inhibition of ciliary function and damage to bronchial epithelium, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] inhibition of mucociliary transport, 23, 24 alteration of respiratory epithelial ion transport, 25, 26 and stimulation of mucus secretion. [27] [28] [29] The phenazine pigments of P. aeruginosa, pyocyanin and 1-hydroxyphenazine, slow cilia in a dose-dependent manner. 7 Pyocyanin causes gradual onset of progressive ciliary slowing and ultimately ciliostasis and epithelial damage. 1-Hydroxyphenazine causes rapid onset of ciliary slowing and dyskinesia with subsequent recovery. These toxins slow tracheal mucus velocity in the anaesthetized guinea pig. 23 Pseudomonas phenazine pigments interact in a proinflammatory manner with neutrophils, intensifying bacterial and neutrophil-mediated injury to epithelium. 30 Pseudomonas proteases 31 and rhamnolipids 24 also inhibit ciliary beating and damage the epithelium.
Pneumolysin, the protein toxin of S. pneumoniae, has cytotoxic and complement-activating domains. The cytotoxic region of the molecule is associated with ciliated epithelial damage. 32 Pneumolysin alone induces the salient histological features of lobar pneumonia without the requirement for the live bacterium. 33 Interestingly, prior immunization with pneumolysin in Freund's adjuvant reduced the severity of the pneumonia. 34 Although these in-vitro observations cannot be extrapolated to man directly, the P. aeruginosa phenazine pigments can be found in the respiratory secretions from patients with bronchiectasis and cystic fibrosis, colonized with the organism, in concentrations sufficient to inhibit ciliary function in vitro. 35, 36 Although much of the information is derived from invitro experiments, the microbial exotoxins responsible for such in-vitro effects can be shown to be active in in-vivo models 23, 24 and to be present in relevant concentrations within secretions from the respiratory tract of patients with bronchiectasis. 35, 36 By such effects bacteria create favourable conditions for colonization and proliferation within the respiratory tract which may be the precursor to acute and chronic infections of the respiratory tract.
The cellular mechanisms by which the Pseudomonas toxins cause epithelial damage and ciliary dysfunction may be enhanced release of reactive oxygen radicals from neutrophil polymorphonuclear leucocytes (PMNLs) situated within the epithelium, as suggested by experiments in sheep. 37 Other experiments 11 using human nasal epithelium have suggested that the mechanism is depletion of adenosine nucleotides (cAMP and ATP) in the ciliated epithelial cells. The cAMP analogue, dibutyryl cAMP, and agents increasing intracellular cAMP are able to prevent the slowing of the ciliary beat and delay the epithelial disruption mediated by Pseudomonas toxins.
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Microbial persistence
Recent work has shown that the majority of bacteria in bronchiectasis appear to persist in mucus and that the organisms do not adhere to normal respiratory epithelium but only to damaged cells-which are extruded out into the mucus. [38] [39] [40] Bacterial fimbriae may confer an advantage in allowing adherence to mucus and damaged cells, but they do not do so with normal respiratory epithelium. [38] [39] [40] [41] Initially, S. pneumoniae adheres to a thick gelatinous mucus layer and slows ciliary beating by release of pneumolysin but does not adhere to epithelial cells or cilia, 16 nor does it cause much epithelial damage. Later, separation of epithelial cell tight junctions occurs with disruption of the epithelium and invasion by the bacterium.
Initially, H. influenzae is associated with the mucus layer on the luminal side of the epithelium, while later it causes epithelial damage and is then able to adhere to these cells and to basement membrane.
Indirect microbial damage
Bacterial colonists can be shown to stimulate a chronic inflammatory response in the host, e.g. by chemo-attraction of granulocytes to the bronchial tree 42 in sufficient numbers to cause tissue damage. There is also evidence for elaboration of molecules by H. influenzae which inactivate neutrophil granulocytes at the site of infection. 43 The host also mounts a florid cell-mediated immune response (consisting mainly of activated CD8 lymphocytes and both antigenpresenting and mature macrophages) in the bronchial wall. 44 Analysis of bronchial secretions expectorated as sputum reveals high concentrations of the cytokines interleukin 1 (IL-1 ) and IL-1 , tumour necrosis factor , IL-6, IL-8 and granulocyte colony-stimulating factor, the levels of IL-8 being particularly high. 45 This cytokine response is held to be responsible for the incessant neutrophil traffic to the bronchial tree. Initially it is likely that this migration of neutrophils is in response to release of chemo-attractants from bacteria 46 but with the passage of time the chemotactic signal almost certainly becomes mainly host-mediated via such cytokine production. This may cause the neutrophil migration to become largely autonomous of the presence of bacteria as suggested by the observation that bacteria but not the IL-8 level can be reduced by successful antimicrobial therapy. 45 Neutrophil migration through the bronchial wall in severe bronchiectasis has been shown by whole body counting to approximate to 50% of circulating cells. 42 This very large cell traffic has significant damaging potential, via released contents such as elastase, for the epithelium 31 and bronchial matrix proteins. Neutrophil elastase also increases the number of mucus-secreting goblet cells in the bronchi 47 and is the most potent secretagogue for mucin secretion so far found. Other neutrophil products such as active oxygen radicals 48 may also play a part in the progressive lung damage seen in bronchiectasis. Some bacterial products appear to be pro-inflammatory in interaction with neutrophils and hence may intensify neutrophil-mediated tissue damage. 30, 49 Hydrogen peroxide (H 2 O 2 ) and hypochlorous acid cause ciliary dyskinesia and slowing. 50 The pneumococcus produces H 2 O 2 and it may therefore be a virulence factor for this bacterium. 50 However, phagocytes are likely to be the most important source of the molecules.
Bioactive phospholipids cause significant dose-dependent slowing of ciliary beating and epithelial damage in vitro, and PMNLs enhance these effects probably by enhanced reactive oxygen radical production. Guinea-pig eosinophils activated by platelet activating factor (PAF) disrupt tracheal epithelium probably by a related mechanism. 51 In the experimental model of bronchiectasis a similar immunopathology develops 4 and this promises to be a useful tool for testing whether such cell-mediated immunity has a damaging role in the natural history of bronchiectasis and what treatments might intervene in the process.
Mucus transportability
The basic underlying abnormality of decreased mucociliary clearance in chronic respiratory infection could be due to defective ciliary function, or to inferior mucus qualities making the latter unsuitable for clearance by cilia, or to both. Recently, an intrinsic abnormality of expectorated mucus has been defined which renders it more slowly transported by cilia. A mucus-depleted bovine tracheal model 52 has been instrumental in demonstrating this abnormally slow-moving mucus to be present in cystic fibrosis, bronchiectasis and chronic bronchitis. Mucus movement appears to be abnormal because of low osmolality which, if rectified, produces a change in the rheology of the mucus, allowing cilia to transport it at normal rate. 53 This might be a route by which the mutated cystic fibrosis gene product has its effect in predisposing to respiratory infection.
Modes of protection
From a knowledge of the mechanisms underlying the pathogenesis of bronchiectasis, it is possible to devise more successful management of chronic lung infection than previously possible. Management 1 consists of: (i) suspecting the presence of bronchiectasis in all patients persistently coughing purulent sputum (but excluding eosinophils as the cause of purulence) and proving it by an imaging technique; (ii) establishing the cause of the bronchiectasis, if possible; (iii) assessing the inflammatory activity of the disease; (iv) treating the patient; and (v) monitoring the result of treatment and modifying treatment if necessary.
Treatment
Conventionally, treatment 1 consists of: (i) specific treatment for the cause, if known (e.g. immunoglobulin reconstitution in hypogammaglobulinaemia); (ii) considering curative surgical resection if disease is localized, and there is no underlying causal or associated disease (including sinusitis) to indicate underlying propensity to develop further bronchiectasis; (iii) postural physiotherapy employing gravity to assist bronchial mucus clearance; (iv) reducing bronchial inflammatory activity with local and/or systemic anti-inflammatory agents; (v) achieving bronchodilatation with bronchodilators; (vi) killing bacteria in the airway secretions using antibiotics, preferably those penetrating mucus efficiently; (vii) treating associated rhinosinusitis to prevent post-nasal drip; (viii) treating associated gastric acid reflux if this is causing reflex or direct stimulation of mucus secretion; (ix) treating other associated disease (e.g. ulcerative colitis); and (x) considering palliative surgical resection of any sump of pus hindering response to medical treatment.
Antimicrobial strategies consist of reducing the microbial load colonizing the airways (which stimulates hostmediated damage) in various ways: (i) antibiotic cover for viral upper/lower respiratory infections in those whose infective exacerbations only occur following these; (ii) elective intermittent ('pulsed') oral or intravenous antibiotic to reduce microbial load and prevent infective exacerbations; (iii) continuous inhaled antibiotic to prolong remissions between infective episodes; and (iv) continuous oral or intravenous antibiotics for the most severely affected patients whose first line clearance mechanisms are insufficient to protect at all against microbial recolonization (such therapy is often achieved through an implanted venous access device).
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More recent treatments that have been considered are discussed in the following sections:
Epithelial cytoprotection. Subinhibitory concentrations of macrolide antibiotics can be shown in vitro to protect the epithelium by a mechanism as yet undetermined although studies have shown various effects of these agents on host defence mechanisms (e.g., see reference 54). These concentrations of antibiotic also inhibit bacterial toxin productions. 55, 56 Salmeterol also protects the epithelium in vitro against the effects of bacterial toxins by 2 -agonistmediated increase of intracellular adenine nucleotides but probably mainly by stabilizing the cell membrane.
Modulation of neutrophil function. Salmeterol stabilizes the cell membrane of neutrophil PMNLs, reducing their activation and respiratory burst, and their reactive oxygen radical production. (Feldman et al. , personal communication).
Direct anti-inflammatory effect on epithelium.
A recent controlled pilot study of inhaled fluticasone in a dose of 1500 mg/day has shown that, in those clinically responding with reduced symptoms of bronchiectasis, there is a significant reduction in inflammatory indices in biopsied bronchial epithelium in bronchiectasis and, in some cases, reduction in cylindrical bronchiectatic changes on CT imaging. (Wells et al., personal communication) .
Mucokinetic agents. Agents that thin the mucus so as to render it more easily coughed up (e.g., recombinant human DNase) have been shown to be effective in cystic fibrosis but not in bronchiectasis of non-cystic fibrosis origin. More promise is held for agents that alter the rheology of mucus by altering its osmolality thus restoring more normal transport of it by cilia. 54 
